Chvála vzdělanosti

Clin Osteol 2018; 23(1): 4

Od Osteologického bulletinu ku Clinical OsteologyEditorial

Clin Osteol 2018; 23(1): 5

Effects of the gut microbiome on the bone tissue metabolismReview articles

Palička Vladimír

Clin Osteol 2018; 23(1): 6-8

The links between different organs and tissues of the human body are multiple and many-sided. Until now, the skeletal system has been considered rather isolated. Recently, the extension of knowledge about the effects of hormones, immunity, nutrition, ions and other factors has considerably advanced. The latest studies demonstrate close relationship between the microbiome, especially the gut microbiome, and bone tissue metabolism. The gut microbiome undoubtedly affects healthy development of bone tissue in childhood and its remodelling in adulthood, absorption of calcium, and production of proinflammatory interleukins including RANKL through influencing...

Secondary osteoporosis in patients with malignanciesReview articles

Špániková Beata

Clin Osteol 2018; 23(1): 9-17

Continual improvement of antineoplastic therapy and early diagnosis of malignancies -⁠ especially in breast and prostate cancer cause better survival but it can caused late toxicity. Estrogens have a dominant position in bone turnover. Using inhibitors of aromatase cause blockade of extragonadal synthesis of estrogens. Also androgen deprivation therapy block production of androgens in men with prostate cancer. Chemotherapy and cancer cells by themselves can caused lowering of BMD (bone mineral density) also and low BMD correlate with low traumatic fractures. These fractures, especially those of hip and spine not only reduce the quality of life,...

Postmenopausal osteoporosis: standard diagnostic and therapeutic practiceGuidelines

Payer Juraj; Killinger Zdenko; Jackuliak Peter; Kužma Martin

Clin Osteol 2018; 23(1): 18-27

The Ministry of Health in cooperation with specialists has been actively engaged in the creation of standard preventive, diagnostic and therapeutic procedures. The standard diagnostic and therapeutic procedures provide a rough guide to the treatment for a diagnosis in question. The Society for Osteoporosis and Metabolic Bone Diseases has prepared a standard diagnostic and therapeutic procedure concerning patients with postmenopausal osteoporosis.

Secondary osteoporosis associated with cancer therapy: a standard diagnostic and therapeutic procedure concerning patients with cancer treatment induced bone lossGuidelines

Špániková Beata, Payer Juraj, Jackuliak Peter, Mego Michal

Clin Osteol 2018; 23(1): 28-31

The Ministry of Health in cooperation with specialists has been actively engaged in the creation of standard preventive, diagnostic and therapeutic procedures. The standard diagnostic and therapeutic procedures provide a rough guide to the treatment for a diagnosis in question. The Society for Osteoporosis and Metabolic Bone Diseases has prepared a standard diagnostic and therapeutic procedure concerning patients with postmenopausal osteoporosis. Key words:androgen-deprivation therapy -⁠ bisphosphonates -⁠ denosumab -⁠ hormonal manipulation -⁠ aromatase inhibitors -⁠ osteoporosis -⁠ cancer treatment...

Long-term denosumab therapy for osteoporosis and its interruption: expert opinion of the Society for Metabolic Bone Diseases working group within the Czech Medical Association of J.E. PurkyněGuidelines

Bayer Milan; Horák Pavel; Palička Vladimír; Pavelka Karel; Pikner Richard; Rosa Jan; Šenk František; Vyskočil Václav; Zikán Vít

Clin Osteol 2018; 23(1): 32-37

One characteristic of bisphosphonates, the most widely used group of antiresorptive drugs for osteoporosis, is their long retention in the skeletal system and persistence of the effect following treatment discontinuation. Compared to bisphosphonates, intervention of denosumab into the bone metabolism is deeper, however it is not deposited in the bone tissue and after its use is discontinued, increase in bone remodelling exceeds the initial level (rebound effect) within 12-18 months from the last dose, which is associated with accelerated decrease in bone mineral density (BMD). A series of case reports and analysis of patients who discontinued the use...

Hypophosphatemic rickets linked to the X (XLH) chromosome -⁠ KRN 23 (burosumab) therapy: expert opinion of the Society for Metabolic Bone Diseases within the Czech Medical Association of J.E. PurkyněGuidelines

Palička Vladimír; Bayer Milan; Rosa Jan; Kutílek Štěpán

Clin Osteol 2018; 23(1): 38-41

Received 5. 9. 2018